baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Regeneron Pharmaceuticals Inc/ US75886F1075 /

6/7/2024 10:00:00 PM	Chg. +2.1600	Volume	Bid11:51:37 PM	Ask11:51:37 PM	Market Capitalization	Dividend Y.	P/E Ratio
1,002.9500USD	+0.22%	250,100 Turnover: 100.02 mill.	960.0000Bid Size: 100	1,011.5000Ask Size: 100	110.51 bill.USD	-	27.07

GlobeNewswire 6/5 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharma...

GlobeNewswire 6/4 Kiniksa Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference

GlobeNewswire 6/3 FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroG...

GlobeNewswire 5/31 Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD

GlobeNewswire 5/31 Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD

GlobeNewswire 5/31 Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type ...

GlobeNewswire 5/31 Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with typ...

GlobeNewswire 5/29 Lynch Carpenter Investigates Claims in Cencora, Inc. Data Breach

GlobeNewswire 5/28 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharma...

GlobeNewswire 5/23 Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Com...

GlobeNewswire 5/22 Invivyd Elects Two New Independent Members to its Board of Directors

GlobeNewswire 5/21 Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update

GlobeNewswire 5/20 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharma...

GlobeNewswire 5/20 Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS...

GlobeNewswire 5/20 Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ...

GlobeNewswire 5/20 Bragar Eagel & Squire, P.C. Is Investigating Zymeworks, Regeneron, Jabil, and DoubleVerify and Encou...

GlobeNewswire 5/17 More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International ...

GlobeNewswire 5/14 Veru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Sci...

GlobeNewswire 5/14 Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer

GlobeNewswire 5/13 Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chroni...

GlobeNewswire 5/10 Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates

GlobeNewswire 5/9 Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company P...

GlobeNewswire 5/8 Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound G...

GlobeNewswire 5/7 Kiniksa Pharmaceuticals to Present at Bank of America Securities 2024 Health Care Conference

GlobeNewswire 5/6 Regeneron Announces Investor Conference Presentations

Regeneron Pharmaceuticals Inc/ US75886F1075 /

If you wish to receive reply to your feedback, please provide your email address.